Sugi Predict

Sugi Predict / Compounds / SCHEMBL533740

SCHEMBL533740

SCHEMBL533740

CCCCCCCCCCCCCCCCCCOC1CC(COc2ccc(C(O)c3ccc(OC)cc3)cc2)CC(OCCCCCCCCCCCCCCCCCC)C1OCCCCCCCCCCCCCCCCCC

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MMP9 P14780 1/20 0.38
▸ MMP8 P22894 1/20 0.38
▸ MMP13 P45452 1/20 0.38
▸ NR5A1 Q13285 1/20 0.37
▸ FAAH O00519 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ PTGER4 P35408 1/20 0.36
▸ PTGER2 P43116 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.35
▸ SLC2A1 P11166 1/20 0.35
▸ PLA2G4B P0C869 2/20 0.35
▸ POLB P06746 1/20 0.35
▸ ACACB O00763 1/20 0.35
▸ TP53 P04637 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ LTA4H P09960 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15908216 0.91 MMP9 (0.38) MMP9MMP8MMP13NR5A1LMNA
SCHEMBL534408 0.89 SLC2A1 (0.40) MMP9MMP8MMP13NR5A1FAAH
SCHEMBL3504560 0.85 FAAH (0.41) MMP9MMP8MMP13FAAHLMNA
SCHEMBL533775 0.83 MMP9 (0.39) MMP9MMP8MMP13FAAHLMNA
SCHEMBL13164734 0.83 MAPK1 (0.47) MMP9MMP8MMP13FAAHLMNA
SCHEMBL2016511 0.81 NPC1 (0.42) NR5A1LMNAALDH1A1TP53
SCHEMBL15908236 0.80 SLC2A1 (0.40) MMP9MMP8MMP13NR5A1LMNA
SCHEMBL533766 0.77 LMNA (0.43) NR5A1LMNAALDH1A1PLA2G4BTP53
SCHEMBL31193361 0.77 CNR2 (0.46) ALDH1A1TSHR
SCHEMBL2019737 0.77 CNR1 (0.46) NR5A1ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9670121-B2 Diphenylmethane compound AJINOMOTO CO., INC. (JP) 2017-06-06 — — US claimed
US-20160060198-A1 DIPHENYLMETHANE COMPOUND AJINOMOTO CO., INC. (JP) 2016-03-03 — — US claimed
US-9169187-B2 Method of making peptides using diphenylmethane compound AJINOMOTO CO., INC. (JP) 2015-10-27 — — US claimed
US-20140213761-A1 DIPHENYLMETHANE COMPOUND AJINOMOTO CO., INC (JP) 2014-07-31 — — US claimed
EP-2415745-A1 DIPHENYLMETHANE COMPOUND Ajinomoto Co., Inc. (JP) 2012-02-08 — — EP claimed
US-20100249374-A1 DIPHENYLMETHANE COMPOUND AJINOMOTO CO., INC. (JP) 2010-09-30 — — US claimed
US-12351601-B2 Method for producing peptide continuously AJINOMOTO CO., INC. (JP) 2025-07-08 — — US disclosed
US-20250188118-A1 LIQUID PHASE PEPTIDE SYNTHESIS METHODS AMGEN INC. (US) 2025-06-12 — — US disclosed
WO-2025122535-A2 LIQUID PHASE PEPTIDE SYNTHESIS METHODS AMGEN INC. (US) 2025-06-12 — — WO disclosed
US-20220041648-A1 METHOD FOR PRODUCING PEPTIDE CONTINUOUSLY AJINOMOTO CO., INC. (JP) 2022-02-10 — — US disclosed
WO-2020218497-A1 METHOD FOR PRODUCING PEPTIDE CONTINUOUSLY 味の素株式会社 2020-10-29 — — WO disclosed
EP-3412689-B1 HYDROGENATED BLOCK-COPOLYMER HAVING ACID ANHYDRIDE GROUP AND USE THEREOF ZEON CORP (JP) 2020-10-14 — — EP disclosed
US-20190203035-A1 BLOCK-COPOLYMER HYDRIDE HAVING ACID ANHYDRIDE GROUP AND USE THEREOF ZEON CORPORATION (JP) 2019-07-04 — — US disclosed
US-20140296483-A1 METHOD FOR REMOVING FMOC GROUP AJINOMOTO CO., INC. (JP) 2014-10-02 — — US disclosed
US-20140213761-A1 DIPHENYLMETHANE COMPOUND AJINOMOTO CO., INC (JP) 2014-07-31 — — US disclosed
US-8722934-B2 Diphenylmethane compound AJINOMOTO CO., INC. (JP) 2014-05-13 — — US disclosed
US-8722934-B2 Diphenylmethane compound AJINOMOTO CO., INC. (JP) 2014-05-13 — — US disclosed
EP-2415745-A1 DIPHENYLMETHANE COMPOUND Ajinomoto Co., Inc. (JP) 2012-02-08 — — EP disclosed
US-20100249374-A1 DIPHENYLMETHANE COMPOUND AJINOMOTO CO., INC. (JP) 2010-09-30 — — US disclosed
US-20100249374-A1 DIPHENYLMETHANE COMPOUND AJINOMOTO CO., INC. (JP) 2010-09-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249374-A1 DIPHENYLMETHANE COMPOUND CCKAR, DNPEP, QPCTL MMP9 4585/4885MMP8 4199/4885MMP13 4365/4885
US-20250188118-A1 LIQUID PHASE PEPTIDE SYNTHESIS METHODS VIP, RNGTT, SSU72 MMP9 2781/4885MMP8 3364/4885MMP13 2705/4885
US-20220041648-A1 METHOD FOR PRODUCING PEPTIDE CONTINUOUSLY VIP, NPPA, NGLY1 MMP9 2268/4885MMP8 2478/4885MMP13 2076/4885
US-20140213761-A1 DIPHENYLMETHANE COMPOUND CCKAR, VIP, CCKBR MMP9 3657/4885MMP8 4073/4885MMP13 3898/4885
US-20160060198-A1 DIPHENYLMETHANE COMPOUND CCKAR, VIP, CCKBR MMP9 3657/4885MMP8 4073/4885MMP13 3898/4885
US-20140296483-A1 METHOD FOR REMOVING FMOC GROUP ESD, HM13, FURIN MMP9 289/4885MMP8 1035/4885MMP13 933/4885
US-12351601-B2 Method for producing peptide continuously VIP, NPPA, NGLY1 MMP9 2268/4885MMP8 2478/4885MMP13 2076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.